Phase I Trial of Periocular Topotecan in Retinoblastoma

Phase 1 Completed 5 enrolled Hospital JP Garrahan

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a dose-escalation study aimed to assess the toxicity (and marginally the activity) of periocular topotecan in patients with relapsed-resistant retinoblastoma.

Timeline

Start: 2007-03
Primary completion: 2007-12
Completion: 2008-04

Publications

Chantada GL, Fandino AC, Carcaboso AM, Lagomarsino E, de Davila MT, Guitter MR, Rose AB, Manzitti J, Bramuglia GF, Abramson DH. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1492-6. doi: 10.1167/iovs.08-2737. Epub 2008 Oct 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Topotecan	Small molecule	0.5 mg	Other
Subject	Topotecan	Small molecule	1 mg	Other
Subject	Topotecan	Small molecule	1.5 mg	Other
Subject	Topotecan	Small molecule	2 mg	Other

Phase I Trial of Periocular Topotecan in Retinoblastoma

Summary

Timeline

Publications

Drugs

Indications